TScan Therapeutics (TCRX) KOL event summary

Introduction and agenda

• Presented updated data from phase I ALLOHA study of TSC-101, focusing on Cohort C and new manufacturing process, and announced plans to initiate a pivotal Phase 3 ALLOHA-2 study within the month.

• Covered overview of the heme malignancy program, manufacturing updates, updated Cohort C data, Phase 3 trial design, market opportunity, and Q&A session.

• Hosted a virtual KOL event featuring Ran Reshef, M.D., M.Sc., and included Q&A with key opinion leaders and clinical investigators.

KOL background and credentials

• Dr. Ran Reshef, Professor of Medicine and Director of Translational Research and Cellular Immunotherapy at Columbia, with over 19 years in transplant and cell therapy.

• Presenters included Gavin MacBeath, Ph.D., Chrystal Louis, M.D., M.P.H., and Shrikanta Chattopadhyay, M.D.

Market insights and analysis

• Market opportunity estimated at 2,350 U.S. patients at launch, expanding to over 5,900/year as additional HLA products launch and transplant rates rise.

• Product pricing anticipated around $700,000 per treatment, in line with other cell therapies.

• Positive clinical data expected to drive increased use of reduced intensity conditioning and haplo/MMUD donors, further expanding the addressable market.

• Emphasized the need for therapies to prevent relapse following allo-HCT, a leading cause of death in this patient population.